The DOI matches its Crossref record; 39 of the 39 references it cites were found in a registry or an index.
Voriconazole in the treatment of fungal eye infections: a review of current literature
Abstract
Atherosclerotic renovascular disease (ARVD) is associated with heart disease. There has been no systematic study of cardiac structure and function in patients with this condition. In this study, the epidemiology of cardiac changes and their relationship to renal function, renovascular anatomy, and BP are delineated. With the use of a cross-sectional design, 79 patients with ARVD and 50 control patients without ARVD underwent echocardiography and 24-h ambulatory BP monitoring. Clinical and biochemical data were collected. Results were analyzed according to renal function, residual renal artery patency, and unilateral or bilateral ARVD. Only 4 (5.1%) patients with ARVD had normal cardiac structure and function. Patients with ARVD (age 70.7 ± 7.5 yr; estimated GFR 36 ± 19 ml/min) had significantly more cardiovascular comorbidity (77.2 versus 42.0%; P < 0.001), greater prevalence of left ventricular (LV) hypertrophy (78.5 versus 46.0%; P < 0.001) and LV diastolic dysfunction (74.6 versus 40.0%; P < 0.001), and greater LV mass index (183 ± 74 versus 116 ± 33 g/m2; P < 0.001) and LV end-diastolic volume index (82 ± 35 versus 34 ± 16 ml/m2; P < 0.001) than control subjects. BP was similar for both patient groups. For patients with ARVD, neither renal function nor renal artery patency predicted a difference in echocardiographic or ambulatory BP monitoring parameters. Patients with bilateral ARVD had greater LV mass index and LV dilation than patients with unilateral disease. Patients with ARVD exhibit a high prevalence of cardiac morphologic and functional abnormalities at early stages of renal dysfunction. Such patients must be identified early in their disease course to allow risk factor modification.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Voriconazole versus Amphotericin B for Primary Therapy of Invasive Aspergillosis
Herbrecht, R., Denning, D. W., Patterson, T. F., Bennett, J. E., Greene, R. E., Oestmann, J.-W., Kern, W. V., Marr, K. A., Ribaud, P., Lortholary, O., et al. (2002) · New England Journal of Medicine · doi:10.1056/nejmoa020191 · Cited by 3,304
Walsh, T. J., Pappas, P., Winston, D. J., Lazarus, H. M., Petersen, F., Raffalli, J., Yanovich, S., Stiff, P., Greenberg, R., Donowitz, G., et al. (2002) · New England Journal of Medicine · doi:10.1056/nejm200201243460403 · Cited by 979
Combination Antifungal Therapy for Invasive Aspergillosis
Marr, K. A., Boeckh, M., Carter, R. A., Kim, H. W., & Corey, L. (2004) · Clinical Infectious Diseases · doi:10.1086/423380 · Cited by 596
Hariprasad, S. M. (2004) · Archives of Ophthalmology · doi:10.1001/archopht.122.1.42 · Cited by 312
Self-citationCuenca-Estrella, M., Gomez-Lopez, A., Mellado, E., Buitrago, M. J., Monzon, A., & Rodriguez-Tudela, J. L. (2006) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.50.3.917-921.2006 · Cited by 298
Posaconazole: a broad-spectrum triazole antifungal
Torres, H. A., Hachem, R. Y., Chemaly, R. F., Kontoyiannis, D. P., & Raad, I. I. (2005) · The Lancet Infectious Diseases · doi:10.1016/s1473-3099(05)70297-8 · Cited by 285
Ullmann, A. J., Cornely, O. A., Burchardt, A., Hachem, R., Kontoyiannis, D. P., Töpelt, K., Courtney, R., Wexler, D., Krishna, G., Martinho, M., et al. (2006) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.50.2.658-666.2006 · Cited by 273
Marangon, F. B., Miller, D., Giaconi, J. A., & Alfonso, E. C. (2004) · American Journal of Ophthalmology · doi:10.1016/j.ajo.2003.11.078 · Cited by 264
Sutton, D. A., Sanche, S. E., Revankar, S. G., Fothergill, A. W., & Rinaldi, M. G. (1999) · Journal of Clinical Microbiology · doi:10.1128/jcm.37.7.2343-2345.1999 · Cited by 255
Espinel-Ingroff, A., Boyle, K., & Sheehan, D. J. (2001) · Mycopathologia · doi:10.1023/a:1010954803886 · Cited by 251
Voriconazole: A New Triazole Antifungal
Sabo, J., & Abdel‐Rahman, S. M. (2000) · Annals of Pharmacotherapy · doi:10.1345/aph.19237 · Cited by 199
Management of endogenous fungal endophthalmitis with voriconazole and caspofungin
Breit, S. M., Hariprasad, S. M., Mieler, W. F., Shah, G. K., Mills, M. D., & Grand, M. G. (2005) · American Journal of Ophthalmology · doi:10.1016/j.ajo.2004.08.077 · Cited by 193
Self-citationVoriconazole -- better chances for patients with invasive mycoses.
Ghannoum, M. A., & Kuhn, D. M. (2002) · PubMed · Cited by 170
Sponsel, W. E., Graybill, J. R., Nevarez, H. L., & Dang, D. (2002) · British Journal of Ophthalmology · doi:10.1136/bjo.86.7.829-a · Cited by 123
Self-citationREIS, A. (2000) · British Journal of Ophthalmology · doi:10.1136/bjo.84.8.928d · Cited by 110
Review of the safety and efficacy of voriconazole
Rathbun, R. C., & Hoffman, H. L. (2002) · Expert Opinion on Investigational Drugs · doi:10.1517/13543784.11.3.409 · Cited by 110
Aqueous and Vitreous Concentrations Following Topical Administration of 1% Voriconazole in Humans
Vemulakonda, G. A., Hariprasad, S. M., Mieler, W. F., Prince, R. A., Shah, G. K., & Gelder, R. N. V. (2008) · Archives of Ophthalmology · doi:10.1001/archophthalmol.2007.8 · Cited by 105
Self-citationSuccessful Treatment of Resistant Ocular Fusariosis With Posaconazole (SCH-56592)
Tu, E. Y., McCartney, D. L., Beatty, R. F., Springer, K. L., Levy, J., & Edward, D. P. (2006) · American Journal of Ophthalmology · doi:10.1016/j.ajo.2006.10.048 · Cited by 103
Durand, M. L., Kim, I. K., D’Amico, D. J., Loewenstein, J. I., Tobin, E. H., Kieval, S. J., Martin, S. S., Azar, D. T., Miller, F. S., Lujan, B. J., et al. (2005) · American Journal of Ophthalmology · doi:10.1016/j.ajo.2005.03.030 · Cited by 92
Marco, F., Pfaller, M. A., Messer, S. A., & Jones, R. N. (1998) · Medical Mycology · doi:10.1080/02681219880000691 · Cited by 90
Intraocular penetration of systemically administered antifungal agents
O’Day, D. M., Head, W. S., Robinson, R. D., Stern, W. H., & Freeman, J. M. (1985) · Current Eye Research · doi:10.3109/02713688508999978 · Cited by 90
Intravitreal Voriconazole for the Treatment of Endogenous Aspergillus Endophthalmitis
Kramer, M., Kramer, M. R., Blau, H., Bishara, J., Axer‐Siegel, R., & Weinberger, D. (2006) · Ophthalmology · doi:10.1016/j.ophtha.2006.01.059 · Cited by 89
Topical Voriconazole as a Novel Treatment for Fungal Keratitis
Sponsel, W. E., Chen, N., Dang, D., Paris, G., Graybill, J. R., Najvar, L. K., Zhou, L., Lam, K.-W., Glickman, R. D., & Scribbick, F. W. (2005) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.50.1.262-268.2006 · Cited by 81
Self-citationGupta, A. K., Kohli, Y., & Batra, R. (2004) · Medical Mycology · doi:10.1080/13693780410001731583 · Cited by 79
Klont, R. R., Eggink, C. A., Rijs, A. J. M. M., Wesseling, P., & Verweij, P. E. (2005) · Clinical Infectious Diseases · doi:10.1086/430062 · Cited by 79
INTRAVITREAL VORICONAZOLE FOR DRUG-RESISTANT FUNGAL ENDOPHTHALMITIS
Sen, P., Gopal, L., & Sen, P. R. (2006) · Retina · doi:10.1097/01.iae.0000250011.68532.a2 · Cited by 76
Nulens, E., Eggink, C. A., Rijs, A. J. M. M., Wesseling, P., & Verweij, P. E. (2003) · Journal of Clinical Microbiology · doi:10.1128/jcm.41.5.2261-2264.2003 · Cited by 68
Safety of intravitreal voriconazole: electroretinographic and histopathologic studies.
Gao, H., Pennesi, M. E., Shah, K. B., Qiao, X., Hariprasad, S. M., Mieler, W. F., Wu, S. M.-S., & Holz, E. R. (2003) · Europe PMC (PubMed Central) · Cited by 67
Self-citationVoriconazole in Fungal Keratitis Caused by Scedosporium apiospermum
Prats, H. C., Tello, F. L., José, A. B. S., Otaolaurruchi, J. S., & Baines, J. P. O. (2004) · Annals of Pharmacotherapy · doi:10.1345/aph.1d128 · Cited by 65
In Vitro Activity of Ravuconazole against 923 Clinical Isolates of Nondermatophyte Filamentous Fungi
Cuenca‐Estrella, M., Gómez‐López, A., Mellado, E., García‐Effrón, G., Monzón, A., & Rodríguez-Tudela, J. L. (2005) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.49.12.5136-5138.2005 · Cited by 51
Fungal endophthalmitis caused byAspergillus ustusin a patient following cataract surgery
Yıldıran, Ş. T., Mutlu, F. M., Saraçlı, M. A., et al. (2006) · Medical Mycology · doi:10.1080/13693780600717161 · Cited by 36
ENDOGENOUS ENDOPHTHALMITIS CAUSED BY SCEDOSPORIUM APIOSPERMUM TREATED WITH VORICONAZOLE
Figueroa, M. S., Fortün, J., CLEMENT, A., et al. (2004) · Retina · doi:10.1097/00006982-200404000-00027 · Cited by 32
Scedosporium apiospermum traumatic endophthalmitis successfully treated with voriconazole
Zarkovic, A., & Guest, S. (2007) · International Ophthalmology · doi:10.1007/s10792-007-9095-0 · Cited by 31
Kim, J. E. (2003) · Archives of Ophthalmology · doi:10.1001/archopht.121.5.735 · Cited by 31
Chen, F. K., Chen, S. D. M., & Tay‐Kearney, M. (2007) · Clinical and Experimental Ophthalmology · doi:10.1111/j.1442-9071.2007.01493.x · Cited by 28
Do climatic variables influence the development of posterior vitreous detachment?
Rahman, R., Ikram, K., Rosen, P., Cortina‐Borja, M., & Taylor, M. E. (2002) · British Journal of Ophthalmology · doi:10.1136/bjo.86.7.829 · Cited by 27
Maesaki, S., Iwakawa, J., Higashiyama, Y., Miyazaki, Y., Yanagihara, K., Tomono, K., Tashiro, T., & Kohno, S. (2000) · Journal of Infection and Chemotherapy · doi:10.1007/pl00012145 · Cited by 27
Endogenous Scedosporium apiospermum Endophthalmitis
Jain, A. (2007) · Archives of Ophthalmology · doi:10.1001/archopht.125.9.1286 · Cited by 25
Use of voriconazole in candida retinitis
Varma, D., Thaker, H., Moss, P., Wedgwood, K. R., & Innes, J. (2004) · Eye · doi:10.1038/sj.eye.6701427 · Cited by 24
Cited by
Pappas, P. G., Kauffman, C. A., Andes, D. R., Clancy, C. J., Marr, K. A., Ostrosky-Zeichner, L., Reboli, A. C., Schuster, M. G., Vazquez, J. A., Walsh, T. J., et al. (2016) · Clinical Infectious Diseases · doi:10.1093/cid/civ933 · Cited by 4,200
Update on the Management of Infectious Keratitis
Austin, A., Lietman, T., & Rose-Nussbaumer, J. (2017) · Ophthalmology · doi:10.1016/j.ophtha.2017.05.012 · Cited by 613
Mycotic keratitis: epidemiology, diagnosis and management
Thomas, P. A., & Kaliamurthy, J. (2013) · Clinical Microbiology and Infection · doi:10.1111/1469-0691.12126 · Cited by 495
Tissue Penetration of Antifungal Agents
Felton, T., Troke, P. F., & Hope, W. W. (2014) · Clinical Microbiology Reviews · doi:10.1128/cmr.00046-13 · Cited by 426
Current Thoughts in Fungal Keratitis: Diagnosis and Treatment
Ansari, Z., Miller, D., & Galor, A. (2013) · Current Fungal Infection Reports · doi:10.1007/s12281-013-0150-1 · Cited by 299
Metadata
- Authors
- Hariprasad, S. M., Mieler, W. F., Lin, T. K., Sponsel, W. E., & Graybill, J. R.
- Venue
- British Journal of Ophthalmology
- Publisher
- BMJ
- Published
- 2008-06-24
- Volume
- 92
- Issue
- 7
- Pages
- 871-878
- ISSN
- 0007-1161 (ISSN-L)
- OpenAlex
- W2160420092
- Cited by
- 263
- References
- 39
- FWCI
- 18.84
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.